ClinicalTrials.gg
Active, not recruitingNCT06748053Updated Oct 26, 2026

A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma

A Phase 2 interventional study of GSK5784283 and Placebo in Asthma, sponsored by GlaxoSmithKline. Active, not recruiting at 137 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Updated Oct 26, 20267 sites added4 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
307
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 262 studies in Asthma by GlaxoSmithKline — 7 open to participants now, 12 under way, 7 of them phase 3. Asthma · GlaxoSmithKline.

Enrollment
75th of 238
307 · median 93
Started
2025
with 1 other
Phase 2
59 of 262
none open now
Primary completion
2026-07
later than 2 of 11 live
Registered
255th of 262
by date

Among the 262 studies in Asthma by GlaxoSmithKline, this one is the 75th largest by enrollment of the 238 interventional ones that give a count, is one of 2 that started in 2025, is one of 59 in phase 2, reaches primary completion later than 2 of the 11 other live ones, and was the 255th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 262 studies in Asthma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 262 studies in Asthma by GlaxoSmithKline, or all of them as a file.
02

Study summary

This study is trying to find the right dose of a long-lasting medicine called GSK5784283 for people with asthma that remains uncontrolled even though they are using regular asthma treatments. GSK5784283 blocks the action of an inflammatory protein called TSLP that may be contributing to your asthma. The study will be conducted in two parts - Part A (dose finding phase) and Part B (extended dosing phase). Part A will assess the lung function, asthma control, participant safety and certain markers of asthma inflammation in the air you breath out and in your blood. Part B will assess the safety and long-term effects of the repeated or single doses of GSK5784283.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • GSK5784283
  • Anti-TSLP antibody
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

  • : Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol. The participant must be willing and able to comply with trial and follow-up procedures.
  • Age: Participants must be 18 to 75 years of age inclusive, at the time of signing the informed consent.
  • Documented physician-diagnosed asthma for >= 2 years that meets the National Heart, Lung, and Blood Institute guidelines
  • Evidence of variable airflow obstruction consistent with asthma.
  • Documented history of asthma exacerbation within 12 months prior to Visit 1.
  • An asthma exacerbation defined as a worsening of asthma symptoms.
  • A well- documented requirement for regular treatment with medium or high-dose ICS for at least 6 months prior to screening.
  • At least one additional maintenance asthma controller medication is required according to standard practice of care (e.g., long-acting beta 2 agonist (LABA), leukotriene receptors antagonists (LTRA), theophylline, long-acting muscarinic antagonist (LAMA), chromones, etc.). Use of additional asthma controller medications must be documented for at least 3 months prior to Visit 1.
  • Weight >=40 kg.
  • Male or eligible Female.
  • Female participants: A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

    • Not a woman of (WONCBP) OR
    • Is a WOCBP and using a method that is highly effective, with a failure rate of \<1%, 28 days prior to the 1st dose of the study drug and during the study intervention period and follow-up period. The investigator should evaluate potential for contraceptive method failure (e.g. non-compliance, recently initiated) in relationship to the first dose of study intervention.
    • A WOCBP must have a negative serum pregnancy test at screening and a highly sensitive pregnancy test ([urine or serum] as required by local regulations) within 24 hours before each dose of study intervention.
    • If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
    • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
    • Contraceptive use by women should be consistent with location regulations regarding the methods of highly effective contraception for those participating in clinical trials.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Any concomitant respiratory disease that in the opinion of the investigator and/or medical monitor will interfere with the evaluation of the product or interpretation of subject safety or study results (e.g., current upper or lower respiratory tract infection, , cystic fibrosis, pulmonary fibrosis, bronchiectasis, allergic bronchopulmonary aspergillosis, Churg-Strauss syndrome, primary ciliary dyskinesia).

Helminth parasitic infection diagnosed within 6 months prior to Visit 1 that has not been treated with, or has failed to respond to, standard of care therapy.

  • Active or latent tuberculosis:

    • Participants with a diagnosis or evidence of active or latent tuberculosis are excluded from the study.
    • Diagnosis of vocal cord dysfunction, dysfunctional breathing, or pseudo resistant asthma.
  • : A current malignancy or previous history of cancer in remission for less than 5 years prior to screening (Participants that had localized carcinoma of the skin which was resected for cure will not be excluded).
  • History of an unresolved infection within 30 days prior to Visit 1.
  • A known immunodeficiency (e.g. - HIV), other than that explained by the use of corticosteroids taken as therapy for asthma.
  • Participants who have known, pre-existing, clinically significant cardiac, endocrine, , rheumatologic, metabolic, neurological, renal, gastrointestinal, hepatic, hematological or any other system abnormalities that are uncontrolled with standard treatment including eosinophilic conditions such as hyper-eosinophilic syndrome (HES) and eosinophilic granulomatosis with polyangiitis (EGPA).
  • Any clinically relevant abnormal findings in physical examination, hematology, clinical chemistry, urinalysis, vital signs at Visit 2 which in the opinion of the investigator, may put the subject at risk because of his/her participation in the study, or may influence the results of the study, or the subject's ability to participate in the study.
  • Receipt of any marketed or investigational biologic agent within 4 months or 5 half-lives prior to Visit 1, whichever is longer and up until the end of study.
  • Receipt of any investigational non-biologic agent within 30 days or 5 half-lives prior to screening, whichever is longer and up until the end of study.
  • Experimental vaccines are not permitted within 30 days prior to randomization and up until the end of the study.
  • Use of medication (e.g., methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid, systemic (oral) corticosteroids) within 3 months prior to Visit 1 and up until the end of study.
  • Systemic corticosteroid burst including taper within 15 days prior to Visit 1 or during the screening/run-in period.
  • Subjects who have not responded to Tezepelumab treatment.
  • Receipt of live or (s) within 30 days prior to randomization or plans to receive such vaccines up until the end of study.
  • A positive human immunodeficiency virus (HIV) test at screening or subject taking antiretroviral medications, as determined by medical history and/or subject's verbal report.
  • Positive test for virus (HBV) defined as either:

    1. positive for hepatitis B surface antigen (HBsAg) OR
    2. positive for HBV DNA
  • Positive antibody test result.
  • Positive Hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.
  • Current smokers (tobacco and marijuana) or former smokers with a smoking history >=10 pack years and subjects using vaping products, including electronic cigarettes.
  • History of chronic alcohol or drug abuse within 2 years.
  • History of severe allergic reaction, anaphylaxis or documented immune complex disease (Type III reactions) to any biologic therapy.
  • History of sensitivity to any component of the investigational product formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor contraindicates their participation.
  • Participants who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations.
  • Participants who meet the following based on results from sample taken at Visit 2:

    1. (ALT) >2x (ULN)
    2. Total >1.5x ULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin \<35%)
    3. Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • >= 450 msec or QTcF >= 480 msec for patients with bundle branch block or an abnormal finding that is considered to be clinically significant and would impact the participant's participation during the study, based on the evaluation of the investigator in the 12-Lead ECG central over-read from screening Visit 2.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
307 participants (actual)

Study arms

  • Experimental
    Part A: Dose Finding - GSK5784283

    Drug: GSK5784283

  • Experimental
    Part A: Dose Finding - Placebo

    Drug: Placebo

  • Experimental
    Part B: Extended Dosing - GSK5784283

    Drug: GSK5784283

  • Experimental
    Part B: Extended Dosing - Placebo

    Drug: Placebo

Interventions

  • GSK5784283 will be administered.

    Also known as: AIO-001, SHR-1905

  • DrugPlacebo

    Placebo will be administered.

06

What researchers measure

Primary outcomes

  1. Part A: Change from baseline in the fraction of exhaled nitric oxide (FeNo)

    Time frame: Baseline (Day 1) and at 2, 4, 8,12, 20 and 26 weeks

Secondary outcomes

  1. Part A: Change from baseline in blood eosinophil counts

    Time frame: Baseline (Day 1) and at 2, 4, 8,12, 20 and 26 weeks

  2. Part A: Change from baseline in the forced expiratory volume (FEV1) [pre-and post-bronchodilator

    Time frame: Baseline (Day 1) and at 2, 4, 8,12, 20 and 26 weeks

  3. Part A: Change from baseline in the forced vital capacity (FVC) [pre-and post-bronchodilator

    Time frame: Baseline (Day 1) and at 2, 4, 8,12, 20 and 26 weeks

  4. Part A: Change from baseline in the 5-item Asthma Control Questionnaire (ACQ-5)

    The ACQ-5 is a five-item questionnaire, which has been developed as a measure of participants' asthma control. The five questions enquire about the frequency and/or severity of symptoms (nocturnal awakening on waking in the morning, activity limitation, and shortness of breath, wheeze) over the previous week. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/ limitation) scale.

    Time frame: Baseline (Day 1) and at 2, 4, 8,12, 20 and 26 weeks

  5. Part A: Maximum Observed Plasma Concentration (Cmax) of GSK5784283

    Time frame: Up to 26 weeks

  6. Part A: Time to Reach Cmax (Tmax) of GSK5784283

    Time frame: Up to 26 weeks

  7. Part A: Area under the curve over the dosing interval (AUC0-tau) of GSK5784283

    Time frame: Up to 26 weeks

  8. Part A & B: Number of participants with treatment emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)

    Time frame: Up to 52 weeks

  9. Part A & B: Number of participants with clinically significant changes in hematology, clinical chemistry and urinalysis

    Time frame: Up to 52 weeks

  10. Part A & B: Number of participants with clinically significant changes in vital signs, including blood pressure, body temperature, and pulse rate

    Time frame: Up to 52 weeks

  11. Part A & B: Number of participants with clinically significant changes in Electrocardiogram (ECG)

    Time frame: Up to 52 weeks

  12. Part A & Part B: Number of participants with treatment-emergent Anti-drug antibodies (ADA) to GSK5784283

    Time frame: Up to 52 weeks

  13. Part A & Part B: Titers of ADA to GSK5784283

    Time frame: Up to 52 weeks

  14. Part A: Number of participants with Neutralizing Antibody (NAb) to GSK5784283

    Time frame: Baseline (Day 1) and at 2, 4, 8,12, 20 and 26 weeks

  15. Part B: Change from baseline in the fraction of exhaled nitric oxide (FeNo)

    Time frame: Baseline (Day 1) and at 2, 4, 8,12, 20, 26, 28, 30, 34, 38, 46, and 52 weeks

  16. Part B: Change from baseline in blood eosinophil counts

    Time frame: Baseline (Day 1) and at 2, 4, 8,12, 20, 26, 28, 30, 34, 38, 46, and 52 weeks

  17. Part B: Ratio to change from baseline in FeNO and blood eosinophil counts

    Time frame: Baseline (Day 1) and 52 weeks

  18. Part B: Change from baseline in the forced expiratory volume (FEV1) [pre-and post-bronchodilator

    Time frame: Baseline (Day 1) and at 2, 4, 8,12, 20, 26, 28, 30, 34, 38, 46, and 52 weeks

  19. Part B: Change from baseline in the forced vital capacity (FVC) [pre-and post-bronchodilator

    Time frame: Baseline (Day 1) and at 2, 4, 8,12, 20, 26, 28, 30, 34, 38, 46, and 52 weeks

  20. Part B: Change from baseline in the 5-item Asthma Control Questionnaire (ACQ-5)

    The ACQ-5 is a five-item questionnaire, which has been developed as a measure of participants' asthma control. The five questions enquire about the frequency and/or severity of symptoms (nocturnal awakening on waking in the morning, activity limitation, and shortness of breath, wheeze) over the previous week. The response options for all these questions consist of a zero (no impairment/limitation) to six (total impairment/ limitation) scale.

    Time frame: Baseline (Day 1) and at 2, 4, 8,12, 20, 26, 34, 46, and 52

  21. Part B: Number of participants with Neutralizing Antibody (NAb) to GSK5784283

    Time frame: Baseline (Day 1) and at 2, 4, 8,12, 20, 26, 28, 30, 34, 38, 46, and 52 weeks

07

Study locations

137 sites
  • GSK Investigational Site
    Little Rock, Arkansas 72205, United States
  • GSK Investigational Site
    Long Beach, California 90815-2521, United States
  • GSK Investigational Site
    Los Angeles, California 90025, United States
  • GSK Investigational Site
    Modesto, California 95350-4439, United States
  • GSK Investigational Site
    Redding, California 96001, United States
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    Sacramento, California 95817-1460, United States
  • GSK Investigational Site
    San Jose, California 95117, United States
  • GSK Investigational Site
    Colorado Springs, Colorado 80923, United States
  • GSK Investigational Site
    Lakewood, Colorado 80228-1813, United States
  • GSK Investigational Site
    Wheat Ridge, Colorado 80033, United States
  • GSK Investigational Site
    New Haven, Connecticut 06510-3206, United States
  • GSK Investigational Site
    Aventura, Florida 33180, United States
  • GSK Investigational Site
    Hialeah, Florida 33012, United States
  • GSK Investigational Site
    Lake Worth, Florida 33460, United States
  • GSK Investigational Site
    Leesburg, Florida 34748, United States
  • GSK Investigational Site
    Miami, Florida 33144, United States
  • GSK Investigational Site
    Miami, Florida 33166-4845, United States
  • GSK Investigational Site
    Miami, Florida 33172, United States
  • GSK Investigational Site
    Miami, Florida 33173-3484, United States
  • GSK Investigational Site
    Plantation, Florida 33324-7006, United States
  • GSK Investigational Site
    Tampa, Florida 33607-6616, United States
  • GSK Investigational Site
    Tampa, Florida 33607, United States
  • GSK Investigational Site
    Skokie, Illinois 60077, United States
  • GSK Investigational Site
    Shreveport, Louisiana 71105, United States
  • GSK Investigational Site
    Lathrup Village, Michigan 48076-4546, United States
  • GSK Investigational Site
    Warren, Michigan 48088, United States
  • GSK Investigational Site
    St Louis, Missouri 63119, United States
  • GSK Investigational Site
    Omaha, Nebraska 68198, United States
  • GSK Investigational Site
    The Bronx, New York 10461, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45236, United States
  • GSK Investigational Site
    DuBois, Pennsylvania 15801-2277, United States
  • GSK Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15241, United States
  • GSK Investigational Site
    Wyomissing, Pennsylvania 19610-3333, United States
  • GSK Investigational Site
    Warwick, Rhode Island 02886, United States
  • GSK Investigational Site
    Greenville, South Carolina 29607, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303-4755, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37909, United States
  • GSK Investigational Site
    Boerne, Texas 78006, United States
  • GSK Investigational Site
    Cypress, Texas 77429, United States
  • GSK Investigational Site
    Dallas, Texas 75225, United States
  • GSK Investigational Site
    Houston, Texas 77058, United States
  • GSK Investigational Site
    Kerrville, Texas 78028, United States
  • GSK Investigational Site
    McKinney, Texas 75069, United States
  • GSK Investigational Site
    San Antonio, Texas 78212, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Sherman, Texas 75092, United States
  • GSK Investigational Site
    American Fork, Utah 84003, United States
  • GSK Investigational Site
    Pleasant View, Utah 84404, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84117, United States
  • GSK Investigational Site
    South Ogden, Utah 84405-4869, United States
  • GSK Investigational Site
    Bellingham, Washington 98225, United States
  • GSK Investigational Site
    Blagoevgrad, 2700, Bulgaria
  • GSK Investigational Site
    Gorna Oryahovitsa, 5100, Bulgaria
  • GSK Investigational Site
    Lovech, 5500, Bulgaria
  • GSK Investigational Site
    Pazardzhik, 4400, Bulgaria
  • GSK Investigational Site
    Plovdiv, 4002, Bulgaria
  • GSK Investigational Site
    Rousse, 7000, Bulgaria
  • GSK Investigational Site
    Rousse, 7002, Bulgaria
  • GSK Investigational Site
    Sofia, 1000, Bulgaria
  • GSK Investigational Site
    Sofia, 1142, Bulgaria
  • GSK Investigational Site
    Sofia, 1233, Bulgaria
  • GSK Investigational Site
    Sofia, 1431, Bulgaria
  • GSK Investigational Site
    Sofia, 1680, Bulgaria
  • GSK Investigational Site
    Stara Zagora, Bulgaria
  • GSK Investigational Site
    Varna, 9000, Bulgaria
  • GSK Investigational Site
    Vratsa, 3000, Bulgaria
  • GSK Investigational Site
    Kelowna, British Columbia V1Y 4N7, Canada
  • GSK Investigational Site
    Ajax, Ontario L1S 2J5, Canada
  • GSK Investigational Site
    London, Ontario N6A 4V2, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 1E2, Canada
  • GSK Investigational Site
    Windsor, Ontario N8X 1T3, Canada
  • GSK Investigational Site
    Trois-Rivières, Quebec G8T 7A1, Canada
  • GSK Investigational Site
    Brandýs nad Labem, 25001, Czechia
  • GSK Investigational Site
    Mladá Boleslav, 293 01, Czechia
  • GSK Investigational Site
    Teplice, 415 01, Czechia
  • GSK Investigational Site
    Fürstenwalde, Brandenburg 15517, Germany
  • GSK Investigational Site
    Darmstadt, Hesse 64283, Germany
  • GSK Investigational Site
    Neu-Isenburg, Hesse 63263, Germany
  • GSK Investigational Site
    Schleswig, Schleswig-Holstein 24837, Germany
  • GSK Investigational Site
    Bendorf, 56170, Germany
  • GSK Investigational Site
    Berlin, 10961, Germany
  • GSK Investigational Site
    Berlin, 12203, Germany
  • GSK Investigational Site
    Frankfurt, 60596, Germany
  • GSK Investigational Site
    Leipzig, 04347, Germany
  • GSK Investigational Site
    Magdeburg, 39120, Germany
  • GSK Investigational Site
    Mainz, 55128, Germany
  • GSK Investigational Site
    München, 81241, Germany
  • GSK Investigational Site
    Chiba, 275-8580, Japan
  • GSK Investigational Site
    Fukui, 910-8526, Japan
  • GSK Investigational Site
    Fukuoka, 806-8501, Japan
  • GSK Investigational Site
    Fukuoka, 811-1394, Japan
  • GSK Investigational Site
    Fukushima, 960-1295, Japan
  • GSK Investigational Site
    Gifu, 509-6134, Japan
  • GSK Investigational Site
    Hiroshima, 734-8530, Japan
  • GSK Investigational Site
    Hokkaido, 064-0804, Japan
  • GSK Investigational Site
    Hyōgo, 653-0013, Japan
  • GSK Investigational Site
    Kagawa, 762-0043, Japan
  • GSK Investigational Site
    Kanagawa, 236-0051, Japan

Showing the first 100 of 137 sites across 9 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to anonymized individual patient-level data (IPD) and related study documents of the eligible studies via the Data Sharing Portal. Details on GSK's data sharing criteria can be found at: https://www.gsk.com/en-gb/innovation/trials/data-transparency/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or terminated asset(s) across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Jul 2026, 17 months.

Of 137 industry-sponsored phase 2 interventional studies under Asthma, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 23. This study's 17 months is close to that.

Counting every sponsor, half of 199 studies reached it within 20 months; a quarter within 12 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2024
First posted
Dec 24, 2024
StartActual
Feb 10, 2025
Primary completionActual
Jul 14, 2026
CompletionEst.
Sep 9, 2027
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
7 sites added, 4 sites removed
Show 7 added (4 Germany, 2 United States, 1 Spain)
  • GSK Investigational Site · Modesto, United States
  • GSK Investigational Site · Tampa, United States
  • GSK Investigational Site · Fürstenwalde, Germany
  • GSK Investigational Site · Darmstadt, Germany
  • GSK Investigational Site · Neu-Isenburg, Germany
  • GSK Investigational Site · Schleswig, Germany
  • GSK Investigational Site · Barcelona, Spain
Show 4 removed
  • GSK Investigational Site · Darmstadt, Germany
  • GSK Investigational Site · Fürstenwalde, Germany
  • GSK Investigational Site · Neu-Isenburg, Germany
  • GSK Investigational Site · Schleswig, Germany
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    7 sites added, 4 sites removed
    Show 7 added (4 Germany, 2 United States, 1 Spain)
    • GSK Investigational Site · Modesto, United States
    • GSK Investigational Site · Tampa, United States
    • GSK Investigational Site · Fürstenwalde, Germany
    • GSK Investigational Site · Darmstadt, Germany
    • GSK Investigational Site · Neu-Isenburg, Germany
    • GSK Investigational Site · Schleswig, Germany
    • GSK Investigational Site · Barcelona, Spain
    Show 4 removed
    • GSK Investigational Site · Darmstadt, Germany
    • GSK Investigational Site · Fürstenwalde, Germany
    • GSK Investigational Site · Neu-Isenburg, Germany
    • GSK Investigational Site · Schleswig, Germany
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06748053
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Feb 10, 2025
Primary completion
Jul 14, 2026
Completion
Sep 9, 2027 (estimated)
Last update
Oct 26, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Felcorekibart

Start the discussion